CD8A and melanoma: We additionally show that CD8+ TIL density is independent of TMB in predicting front-line anti-PD-1 response, suggesting that these 2 biomarkers capture distinct features of neoantigenicity and T-cell activation in inflamed tumors such as melanoma.